CD276 and prostate carcinoma: Similarly, ifinatamab DXd (I-DXd, DS-7300a) is a B7-H3-targeting ADC that has demonstrated promising preclinical and early clinical efficacy, especially in solid tumors with high B7-H3 expression such as lung and prostate cancers [24].